Expertise in
4
conditions

Dr. Stacy Moulder

Internal Medicine
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Expertise in
4
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Stacy Moulder is a primary care provider, practicing in Internal Medicine in Cary, North Carolina.

Dr. Moulder is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and HER-2 Positive Breast Cancer.

She is actively involved in clinical research, co-authoring 118 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III)
Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III)
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Procedure, Other
Study Phase: Phase 2
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drugs: Atezolizumab, Nab-paclitaxel
Study Phase: Phase 2
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug, Procedure, Other
Study Phase: Not Applicable
Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Everolimus, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-In Cohort to Establish Activity in Patients With Metastatic TNBC
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

118 Total Publications

Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
Journal: JCO precision oncology
Published: December 18, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Shreyaskumar Patel
Internal Medicine
Expertise in
26
conditions
Dr. Shreyaskumar Patel
Internal Medicine

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shreyaskumar Patel is an Internal Medicine provider practicing medicine in Cary, North Carolina. Dr. Patel is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Osteotomy.

Expertise in
22
conditions
Dr. Jan Burger
Internal Medicine
Expertise in
22
conditions
Dr. Jan Burger
Internal Medicine

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jan Burger is an Internal Medicine provider practicing medicine in Cary, North Carolina. Dr. Burger is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Angioplasty.

Expertise in
14
conditions
Dr. Paul Corn
Internal Medicine
Expertise in
14
conditions
Dr. Paul Corn
Internal Medicine

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Corn is an Internal Medicine provider practicing medicine in Cary, North Carolina. Dr. Corn is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Stacy Moulder

How do I make an appointment with Dr. Stacy Moulder?

You can book an appointment with Dr. Stacy Moulder by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stacy Moulder a top-rated expert for Triple-Negative Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stacy Moulder is classified as an Elite expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stacy Moulder specialize in?

While Dr. Stacy Moulder is a Internal Medicine, they have specific expertise in Triple-Negative Breast Cancer, Breast Cancer, and PIK3CA-Related Overgrowth Spectrum. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Stacy Moulder participate in research or clinical trials?

Yes. Dr. Stacy Moulder has published 118 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Dr. Stacy Moulder's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stacy Moulder accept my insurance?

Dr. Stacy Moulder accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moulder's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile